![Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2021/4/25/saupload_U22pq7urChUehpbRybf77rsWHgCPpfVvXu7oYf2ZN_d-7JloxsNAgsVg2jM83Fu9d9wZ7AeHZ50Z_aaZx0fQvHiIqA2Wer-bij4NvomBpxAl7EoVzrz6xGcE-wQGAkMHlYvVY4Rd.png)
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
![FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire](https://mms.businesswire.com/media/20210701005217/en/889083/22/4357884cpuma_logo_JPEG.jpg)
FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire
![Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2021/4/25/saupload_zys-A0tTqP8PWlrKLGfU8XarhV75bml0GYT6UZXNdTCeU2AaCXx_644abKUiyEdFCXTOTLutlWDqvkveyTHWK0PYMs5db5WuIcg_P_sz1aH9ATSAfg5L9AuFRgTc-G3-cE9vOVv7.png)